Tocagen is developing Retroviral Replicating Vectors with one or more therapeutic genes against validated targets which are inhibitors of the immune system (“immune system brakes”).
These products are designed to activate the immune system selectively against the tumor without causing clinically meaningful autoimmunity. In contrast, systemically administered immunotherapeutics in development by others activate the immune system more generally and are therefore less likely to achieve anticancer specificity and may have very serious off-target side effects that activate the immune system against healthy tissue (autoimmunity).
Our lead products, “Toca 541” is under preclinical development and we plan to start clinical trials as soon as possible.
Brain Cancer (High Grade Glioma)